A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

What is the purpose of this trial?

Brief Summary:

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF), including but not limited to those who are heterozygous for the F508del mutation


Participation Guidelines

Ages: 12 years and older

Gender: Both


Vertex Pharmaceuticals Incorporated

Start Date: 09/17/2018

End Date: 04/24/2021

Last Updated: 12/20/2018

Study HIC#: 2000022968

Get Involved

For more information about this study, contact:
Catalina Guzman
+1 203-836-7172
catalina.guzman@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Marie Egan

Principal Investigator

Sub-Investigators